subscribeSubscribe
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten
GLOBENEWSWIRE
24 Oct 2023
Share Share
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten
GLOBENEWSWIRE
28 Aug 2023
Share Share
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten)

Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten)
BUSINESSWIRE
28 Aug 2023
Share Share
BMS` Camzyos (mavacamten) Receives Approval in Europe

BMS` Camzyos (mavacamten) Receives Approval in Europe
EMA
07 Aug 2023
Share Share
Bristol Myers Squibb`s Camzyos (mavacamten) Receives Approval in Europe

Bristol Myers Squibb`s Camzyos (mavacamten) Receives Approval in Europe
EMA
24 Jul 2023
Share Share
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS

Bristol Myers Squibb Receives European Commission Approval of CAMZYOS
FINANCE YAHOO
27 Jun 2023
Share Share
USFDA of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS®

USFDA of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS®
BUSINESSWIRE
15 Jun 2023
Share Share
Bristol`s Camyzos picks up early nod from England`s NICE

Bristol`s Camyzos picks up early nod from England`s NICE
Eric Sagonowsky FIERCE PHARMA
03 Jun 2023
Share Share
LianBio Announces Marketing Approval of CAMZYOS in the Macau SAR of China

LianBio Announces Marketing Approval of CAMZYOS in the Macau SAR of China
GLOBENEWSWIRE
11 May 2023
Share Share
BMS Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®

BMS Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®
BUSINESSWIRE
26 Apr 2023
Share Share